# US 2021/0069345 A1 · Hexameric tetrahedral rna nanostructures

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0069345 A1
- Document ID: US20210069345A1
- Status: Published application
- Kind: A1
- Application number: 17/053,615
- Filed: 2019-05-08
- Published: 2021-03-11
- Earliest claimed: 2018-05-08
- Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services; The Regents of the University of California
- Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services; The Regents of the University of California
- Inventors: Bruce A. Shapiro; Paul J. Zakrevsky; Luc Jaeger
- Web page: https://patentgrep.com/patent/US20210069345A1

## CPC

- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 47/6925: {the form being a microcapsule, nanocapsule, microbubble or nanobubble}
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed are nanostructures comprising a ribonucleic acid (RNA) scaffold comprising a hexameric tetrahedral core. The tetrahedral core may comprise four hexameric RNA nanorings linked together. Related pharmaceutical compositions, methods of modulating the expression of a target gene in a mammal, methods of treating or preventing a disease in a mammal, and methods of producing a hexameric tetrahedral RNA nanostructure are also disclosed.

## Claims

### Claim 1

A nanostructure comprising a ribonucleic acid (RNA) scaffold comprising a hexameric tetrahedral core,
wherein the tetrahedral core comprises four hexameric RNA nanorings linked together.

### Claim 2 (depends on 1)

The nanostructure according to claim 1, wherein the four hexameric RNA nanorings linked are together via “H”-shaped cross-over monomers,
wherein each “H”-shaped cross-over monomer comprises two UA-handle three-way junctions (3WJs) linked together by a 7 base pair bridge to form the “H”-shaped cross-over monomer.

### Claim 3

A nanostructure comprising a ribonucleic acid (RNA) scaffold comprising a hexameric tetrahedral core, wherein the tetrahedral core comprises:
first, second, third, fourth, fifth, and sixth cross-over monomers;
first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, and twelfth dumbbell monomers;
wherein the first, second, and third dumbbell monomers and the first, second, and sixth cross-over monomers together form a first hexameric nanoring;
wherein the fourth, fifth, and sixth dumbbell monomers and the fourth, fifth, and sixth cross-over monomers together form a second hexameric nanoring;
wherein the seventh, eighth, and ninth dumbbell monomers and the first, third, and fifth cross-over monomers together form a third hexameric nanoring;
wherein the tenth, eleventh, and twelfth dumbbell monomers and the second, third, and fourth cross-over monomers together form a fourth hexameric nanoring; and
wherein each cross-over monomer is shared by two of the hexameric rings to link the hexameric nanorings together to form the hexameric tetrahedral core.

### Claim 4 (depends on 3)

The nanostructure of claim 3, wherein each dumbbell monomer comprises a helix comprising first and second ends, wherein the helix of each dumbbell monomer is capped at both ends with a kissing loop.

### Claim 5 (depends on 4)

The nanostructure of claim 4, wherein the helix of each dumbbell monomer is a 15 base pair (bp) helix and each kissing loop of each dumbbell monomer is a 7 nucleotide (nt) kissing loop.

### Claim 6 (depends on 4)

The nanostructure of claim 4, wherein each kissing loop has a nucleotide sequence that is unique in any one of the nanorings.

### Claim 7 (depends on 3)

The nanostructure of claim 3, wherein each crossover monomer comprises first, second, third, and fourth kissing loops and first and second UA-handle three-way junctions (UAh-3WJs).

### Claim 8 (depends on 7)

The nanostructure of claim 7, wherein the first UAh-3WJ is positioned symmetrically to the second UAh-3WJ in each crossover monomer.

### Claim 9 (depends on 7)

The nanostructure of claim 7, wherein:
the first UAh-3WJ is positioned between a first 8 bp side helix and a first 6 bp side helix, and
the second UAh-3WJ is positioned between a second 8 bp side helix and a second 6 bp side helix.

### Claim 10 (depends on 7)

The nanostructure of claim 7, wherein:
a first pair of the four kissing loops of each crossover monomer each comprise a copy of the same first nucleotide sequence, and
a second pair of the four kissing loops of each crossover monomer each comprise a copy of the same second nucleotide sequence, which is different from the first nucleotide sequence.

### Claim 11 (depends on 10)

The nanostructure of claim 10, wherein:
the first pair of the four kissing loops of each crossover monomer are positioned symmetrically to one another; and
the second pair of the four kissing loops of each crossover monomer are positioned symmetrically to one another.

### Claim 12 (depends on 7)

The nanostructure of claim 7, wherein the UAh-3WJs are Escherichia coli 23S rRNA UAh-3WJs.

### Claim 13 (depends on 7)

The nanostructure of claim 7, wherein the first and second UAh-3WJs of each crossover monomer are connected by a bridge helix.

### Claim 14

(canceled)

### Claim 15 (depends on 7)

The nanostructure of claim 7, wherein each crossover monomer is a single RNA strand.

### Claim 16 (depends on 1)

The nanostructure of claim 1, wherein:
(i) two of the four kissing loops of each crossover monomer, and one of the two UAh-3WJs of each crossover monomer, are positioned in one of the hexameric nanorings, and
(ii) the other two of the kissing loops of each crossover monomer, and the other one of the UAh-3WJs of each crossover monomer, are positioned in another one of the hexameric nanorings which is adjacent to, and directly linked to, the hexameric nanoring of (i).

### Claim 17 (depends on 1)

The nanostructure of claim 1, wherein:
a first pair of the six cross-over monomers comprise copies of the same first cross-over monomer nucleotide sequence;
a second pair of the six cross-over monomers comprise copies of the same second cross-over monomer nucleotide sequence; and
a third pair of the six cross-over monomers comprise copies of the same third cross-over monomer nucleotide sequence,
wherein the first, second, and third cross-over monomer nucleotide sequences are different from one another.

### Claim 18 (depends on 1)

The nanostructure of claim 1, wherein:
a first four of the twelve dumbbell monomers comprise copies of the same first dumbbell monomer nucleotide sequence;
a second four of the twelve dumbbell monomers comprise copies of the same second dumbbell monomer nucleotide sequence;
a third four of the twelve dumbbell monomers comprise copies of the same third dumbbell monomer nucleotide sequence;
wherein the first, second, and third dumbbell monomer nucleotide sequences are different from one another.

### Claim 19 (depends on 1)

The nanostructure of claim 1, wherein the bridge helix connecting the first and second UAh-3WJs is a 7 bp helix.

### Claim 20 (depends on 1)

The nanostructure of claim 1, wherein the tetrahedral core comprises four, eight, or twelve monomer arms.

### Claim 21 (depends on 20)

The nanostructure of claim 20, wherein the four, eight, or twelve monomer arms are each functionalized with one or more of (a) an RNAi substrate, (b) targeting moieties, (c) imaging probes, (d) conjugated proteins, and (e) polymers.

### Claim 22 (depends on 21)

The nanostructure of claim 21, wherein the RNAi substrate comprises Dicer substrate RNA (DsiRNA).

### Claim 23 (depends on 20)

The nanostructure of claim 20, wherein the twelve monomer arms are each functionalized with DsiRNA.

### Claim 24 (depends on 3)

The nanostructure of claim 3, wherein at least one of (a) the first, second, third, fourth, fifth, and sixth cross-over monomers, and/or at least one of (b) first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, and twelfth dumbbell monomers comprises a continuous sequence.

### Claim 25 (depends on 1)

A composition comprising (a) the nanostructure of claim 1, and (b) a pharmaceutically acceptable carrier.

### Claim at position 26

26-30. (canceled)

### Claim 31

A method of producing a hexameric tetrahedral RNA nanostructure comprising:
(a) forming “H”-shaped cross-over monomers, wherein each “H”-shaped cross-over monomer comprises two UA-handle three-way junctions (3WJs) linked together by a 7 base pair bridge to form the “H”-shaped cross-over monomer;
(b) forming hexameric RNA nanorings, wherein each hexameric RNA nanoring includes three of the “H”-shaped cross-over monomers; and
assembling the hexameric tetrahedral RNA nanostructure, wherein the hexameric tetrahedral RNA nanostructure comprises four of the hexameric RNA nanorings linked together via the “H”-shaped cross-over monomers.

### Claim 32 (depends on 1)

A method of treating or preventing a disease in a mammal comprising administering the nanostructure of claim 1 to the mammal in an amount effective to treat or prevent the disease in the mammal.

### Claim 33 (depends on 32)

The method of claim 32, wherein the disease is cancer.

### Claim 34 (depends on 32)

The method of claim 32, wherein the cancer is breast cancer.

### Claim 35 (depends on 32)

The method of claim 32, wherein the disease is a viral disease.
